PMID- 20922625
OWN - NLM
STAT- MEDLINE
DCOM- 20110201
LR  - 20161125
IS  - 1439-1902 (Electronic)
IS  - 0171-6425 (Linking)
VI  - 58
IP  - 7
DP  - 2010 Oct
TI  - Long-term outcomes following repair or replacement in degenerative mitral valve 
      disease.
PG  - 415-21
LID - 10.1055/s-0029-1240925 [doi]
AB  - BACKGROUND: We studied whether mitral valvuloplasty (MVP) was superior to mitral 
      valve replacement (MVR) in patients with degenerative mitral regurgitation (MR), 
      and analyzed the independent risk factors for survival and reoperation. METHODS: 
      326 patients with degenerative MR underwent MVP (n = 241), mitral valve 
      replacement (MVR) (n = 78) or emergent MVR due to failure of repair (EMVR). 
      Clinical data were analyzed retrospectively. RESULTS: Thirty-day mortality was 
      lower after MVP (2.5 %) compared to MVR (9.0 %) ( P < 0.05). Late survival at 1 
      and 5 years in the MVP group was 94.4 % and 84.3 % versus 80.4 % and 64.6 % in 
      the MVR group ( P < 0.05), respectively. After adjusting the baseline 
      characteristics by the propensity score method, a significant survival benefit 
      was found for patients who underwent MVP. Multivariable analysis showed that MVR 
      was an independent predictor of thirty-day mortality and survival. There was no 
      significant difference in thirty-day mortality and survival between the EMVR and 
      MVR groups. The need for reoperation was not significantly different between the 
      MVP and MVR groups. In the MVP group, the risk factors for survival and 
      reoperation were identified. CONCLUSIONS: MVP is superior to MVR for the 
      treatment of degenerative MR despite the impact of repair failure. Age less than 
      60 years, ring size to body surface area greater than 19.0, absence of a 
      prosthetic ring and residual MR at the end of surgery (>/= 1/4) reduce the 
      durability of MVP.
CI  - (c) Georg Thieme Verlag KG Stuttgart . New York.
FAU - Zhou, Y X
AU  - Zhou YX
AD  - Service de Chirurgie Cardiovasculaire B, Centre Hospitalier Universitaire de 
      Rangueil, Toulouse, France. zh_yongxin@yahoo.com.cn
FAU - Leobon, B
AU  - Leobon B
FAU - Berthoumieu, P
AU  - Berthoumieu P
FAU - Roux, D
AU  - Roux D
FAU - Glock, Y
AU  - Glock Y
FAU - Mei, Y Q
AU  - Mei YQ
FAU - Wang, Y W
AU  - Wang YW
FAU - Fournial, G
AU  - Fournial G
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20101004
PL  - Germany
TA  - Thorac Cardiovasc Surg
JT  - The Thoracic and cardiovascular surgeon
JID - 7903387
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Chi-Square Distribution
MH  - Echocardiography, Doppler
MH  - Female
MH  - *Heart Valve Prosthesis Implantation/adverse effects/mortality
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Mitral Valve/diagnostic imaging/*surgery
MH  - *Mitral Valve Annuloplasty/adverse effects/mortality
MH  - Mitral Valve Insufficiency/diagnostic imaging/mortality/*surgery
MH  - Propensity Score
MH  - Proportional Hazards Models
MH  - Reoperation
MH  - Retrospective Studies
MH  - Risk Assessment
MH  - Risk Factors
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2010/10/06 06:00
MHDA- 2011/02/02 06:00
CRDT- 2010/10/06 06:00
PHST- 2010/10/06 06:00 [entrez]
PHST- 2010/10/06 06:00 [pubmed]
PHST- 2011/02/02 06:00 [medline]
AID - 10.1055/s-0029-1240925 [doi]
PST - ppublish
SO  - Thorac Cardiovasc Surg. 2010 Oct;58(7):415-21. doi: 10.1055/s-0029-1240925. Epub 
      2010 Oct 4.